The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis
Paloma Pérez‐Domper(Instituto Cajal), José Luís Trejo(Consejo Superior de Investigaciones Científicas), Simona Gradari(Consejo Superior de Investigaciones Científicas), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Marı́a L. de Ceballos(Instituto Cajal), Carmen Gil(Instituto de Salud Carlos III)
Cited by 30
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes
|Autophagy|2016|409
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334